Detalhe da pesquisa
1.
Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma.
Int J Mol Sci
; 22(3)2021 Jan 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-33499253
2.
A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization.
Mol Ther
; 25(8): 1946-1958, 2017 08 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28506593
3.
CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an "Off the Shelf" Therapy for Multiple Myeloma.
Hemasphere
; 5(7): e596, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34131635
4.
Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant.
Hemasphere
; 5(5): e561, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33898931
5.
Bone Marrow Mesenchymal Stromal Cells Can Render Multiple Myeloma Cells Resistant to Cytotoxic Machinery of CAR T Cells through Inhibition of Apoptosis.
Clin Cancer Res
; 27(13): 3793-3803, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33883175
6.
Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence.
Sci Transl Med
; 13(623): eabh1962, 2021 12 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34878825
7.
Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Clin Cancer Res
; 25(13): 4014-4025, 2019 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30979735
8.
Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design.
PLoS One
; 13(5): e0197349, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29847570